Possibilities of early diagnosis of chronic heart failure and chronic kidney disease in patients with type 2 diabetes mellitus at the hospital stage
- 作者: Demidova T.Y.1, Izmailova M.Y.1, Antsiferov M.B.2
-
隶属关系:
- N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia
- Endocrinological Dispensary of the Department of Healthcare of Moscow
- 期: 卷 9, 编号 9 (2023)
- 页面: 16-28
- 栏目: ORIGINAL STUDIES
- URL: https://journals.eco-vector.com/2412-4036/article/view/626087
- DOI: https://doi.org/10.18565/therapy.2023.9.16-28
- ID: 626087
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
Diabetes mellitus type 2 (T2 DM) is one of the most common and severe metabolic diseases, which is a recognized risk factor for cardiovascular complications and the development of chronic kidney disease (CKD).
Objective: to diagnose chronic heart failure (CHF) and CKD in patients with T2 DM at the inpatient stage, during hospitalization in the Department of endocrinology of V.P. Demikhov City Clinical Hospital (Moscow), and the appointment of effective organoprotective therapy.
Material and methods. All patients were examined in accordance with the standards and procedures for providing medical care. The main parameters of carbohydrate and lipid metabolism were assessed. An echocardiography was performed with assessment of standard indicators of systolic and diastolic heart function and a blood test for NTproBNP. GFR was calculated using the CKD-EPI formula and the A/Cr ratio in a single portion of urine was determined.
Results. Among patients hospitalized in the endocrinology department with a diagnosis of T2 DM, 168 people met the criteria for an extensive diagnostic search of whom 80 had a diagnosis of CHF and/or CKD established or confirmed. The average age of patients with cardiorenal pathology was 70±8,99 years, duration of T2 DM was 11 [5; 20] years. The age of onset of diabetes was 57,2±10,3 years. According to the laboratory and instrumental examination, 33,93% had CHF, of which it was first detected in 10,12% of patients and in 23,83% CHF was confirmed and excluded in 66%. At the same time, CKD was detected in 39,52% of cases, newly diagnosed CKD accounted for 7,14%, 32,14% had a history of renal dysfunction of varying severity, and 60,71% did not have CKD detected.
Conclusion. There was a high detection rate of CHF and CKD in patients with T2 DM who were hospitalized in the endocrinology department for inpatient treatment with a more expanded diagnostic search, which dictates the need for a more thorough examination of patients for the presence of CHF.
全文:
作者简介
Tatyana Demidova
N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia
编辑信件的主要联系方式.
Email: t.y.demidova@gmail.com
ORCID iD: 0000-0001-6385-540X
MD, Professor, Head of the Department of Endocrinology of the Faculty of General Medicine
俄罗斯联邦, MoscowMaryam Izmailova
N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia
Email: maremizm@gmail.com
ORCID iD: 0000-0002-1385-0245
Assistant at the Department of Endocrinology of the Faculty of General Medicine
俄罗斯联邦, MoscowMikhail Antsiferov
Endocrinological Dispensary of the Department of Healthcare of Moscow
Email: antsiferov@rambler.ru
ORCID iD: 0000-0002-9944-2997
MD, Professor, Endocrinologist
俄罗斯联邦, Moscow参考
- Дедов И.И., Шестакова М.В., Майоров А.Ю. с соавт. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й выпуск. Сахарный диабет. 2023; 26(S2): 1–231. [Dedov I.I., Shestakova M.V., Mayorov A.Yu. et al. Standards of specialized diabetes care. 11th edition. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. Sakharnyy diabet = Diabetes Mellitus. 2023; 26(S2): 1–231 (In Russ.)]. https://dx.doi.org/10.14341/DM13042.
- Marassi M., Fadini G.P. The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc Diabetol. 2023; 22(1): 195. https://dx.doi.org/10.1186/s12933-023-01937-x.
- Kadowaki T., Maegawa H., Watada H. et al. Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan. Diabetes Obes Metab. 2022; 24(12): 2283–96. https://dx.doi.org/10.1111/dom.14829.
- Kannel W.B., Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol. 1974; 34(1): 29–34. https://dx.doi.org/10.1016/0002-9149(74)90089-7.
- Stratton I.M., Adler A.I., Neil H.A. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000; 321(7258): 405–12. https://dx.doi.org/10.1136/bmj.321.7258.405.
- Valencia W.M., Florez H. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. BMJ. 2017: 356: i6505. https://dx.doi.org/10.1136/bmj.i6505.
- Saran R., Robinson B., Abbott K.C. et al. US Renal Data System 2018 Annual Data Report: Epidemiology of kidney disease in the United States. Am J Kidney Dis. 2019; 73(3 Suppl 1): A7–8. https://dx.doi.org/10.1053/j.ajkd.2019.01.001.
- Birkeland K.I., Bodegard J., Eriksson J.W. et al. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. Diabetes Obes Metab. 2020; 22(9): 1607–18. https://dx.doi.org/10.1111/dom.14074.
- Gourdy P., Darmon P., Dievart F. et al. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). Cardiovasc Diabetol. 2023; 22(1): 79. https://dx.doi.org/10.1186/s12933-023-01798-4.
- Демидова Т.Ю., Измайлова М.Я. Структура распространенности сердечно-сосудистых заболеваний и хронической болезни почек у пациентов с сахарным диабетом 2-го типа стационарного звена. Терапия. 2022; 8(8): 20–31. [Demidova T.Yu., Izmaylova M.Ya. The structure of the prevalence of cardiovascular diseases and chronic kidney disease in patients with type 2 diabetes mellitus in the stationary care. Terapiya = Therapy. 2022; 8(8): 20–31 (In Russ.)]. https://dx.doi.org/10.18565/therapy.2022.8.20-31. EDN: EWYPHA.
- Aguilar D., Bozkurt B., Ramasubbu K., Deswal A. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol. 2009; 54(5): 422–28. https://dx.doi.org/10.1016/j.jacc.2009.04.049.
补充文件
